Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in... Letters 2. Huang CC, Kong MX, Zhou M, et al. Gleason score 3 + 4=7 prostate cancer Antonio Macciò, MD with minimal quantity of Gleason pattern 4 on needle biopsy is associated with Clelia Madeddu, MD low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol. 2014;38 (8):1096-1101. Author Affiliations: Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy (Macciò); Department of Medical Sciences Future Prospects for PD-1 Targeting, Macrophage and Public Health, University of Cagliari, Cagliari, Italy (Madeddu). Infiltration, and IDO Pathway Activation in Patients Corresponding Author: Antonio Macciò, MD, Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, via Jenner, Cagliari 09100, Italy With Sarcomas (antoniomaccio56@gmail.com). To the Editor We read with interest the article by Toulmonde and Published Online: June 14, 2018. doi:10.1001/jamaoncol.2018.0875 colleagues assessing the efficacy and safety of anti–programmed Conflict of Interest Disclosures: None reported. cell death protein 1 (PD-1) antibody and metronomic cyclo- 1. Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage phosphamide in patients with advanced soft-tissue sarcomas. infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93-97. We found the rationale of this combination approach interest- 2. Macciò A, Lai P, Santona MC, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas

Macciò, Antonio; Madeddu, Clelia
JAMA Oncology , Volume 4 (8) – Aug 14, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/future-prospects-for-pd-1-targeting-macrophage-infiltration-and-ido-V0100Cml35
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.0875
Publisher site
See Article on Publisher Site

Abstract

Letters 2. Huang CC, Kong MX, Zhou M, et al. Gleason score 3 + 4=7 prostate cancer Antonio Macciò, MD with minimal quantity of Gleason pattern 4 on needle biopsy is associated with Clelia Madeddu, MD low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol. 2014;38 (8):1096-1101. Author Affiliations: Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy (Macciò); Department of Medical Sciences Future Prospects for PD-1 Targeting, Macrophage and Public Health, University of Cagliari, Cagliari, Italy (Madeddu). Infiltration, and IDO Pathway Activation in Patients Corresponding Author: Antonio Macciò, MD, Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, via Jenner, Cagliari 09100, Italy With Sarcomas (antoniomaccio56@gmail.com). To the Editor We read with interest the article by Toulmonde and Published Online: June 14, 2018. doi:10.1001/jamaoncol.2018.0875 colleagues assessing the efficacy and safety of anti–programmed Conflict of Interest Disclosures: None reported. cell death protein 1 (PD-1) antibody and metronomic cyclo- 1. Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage phosphamide in patients with advanced soft-tissue sarcomas. infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93-97. We found the rationale of this combination approach interest- 2. Macciò A, Lai P, Santona MC,

Journal

JAMA Oncology – American Medical Association

Published: Aug 14, 2018

References

  • Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial
    Toulmonde, M; Penel, N; Adam, J
  • High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer
    Macciò, A; Lai, P; Santona, MC; Pagliara, L; Melis, GB; Mantovani, G
  • Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress
    Mantovani, G; Macciò, A; Madeddu, C
  • Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer
    Mantovani, G; Macciò, A; Lai, P
  • Sensitizing protective tumor microenvironments to antibody-mediated therapy
    Pallasch, CP; Leskov, I; Braun, CJ